How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/relapsed-or-refractory-t-cell-leukemia-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Relapsed or refractory T-cell leukemia-lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Relapsed or refractory T-cell leukemia-lymphoma (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Relapsed or refractory T-cell leukemia-lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Ezharmia	VALEMETOSTAT	Daiichi Sankyo		Histone-lysine N-methyltransferase EZH2
Chidamide	Chidamide	Sun Yat-sen University		Nicotinamide phosphoribosyltransferase, Histone deacetylase 1, Histone deacetylase 10

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Daiichi Sankyo · 1 drug in Relapsed or refractory T-cell leukemia-lymphoma
Sun Yat-sen University · 1 drug in Relapsed or refractory T-cell leukemia-lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Relapsed or refractory T-cell leukemia-lymphoma:

Cite this brief

Drug Landscape (2026). Relapsed or refractory T-cell leukemia-lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/relapsed-or-refractory-t-cell-leukemia-lymphoma. Accessed 2026-06-10.

Relapsed or refractory T-cell leukemia-lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing